Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning, everyone, and welcome to our Q3 2025 conference call. Our CFO, Peter Delhi, and I, Gavin O'Dowd, will take you through our results starting at slide four. I would like to focus on four key aspects of our operational highlights, beginning first with our Nicotine Pouches Q3 volume, which experienced a year-on-year growth of 21% on a like-for-like basis. It should be noted that Q3 last year had an exceptionally high traffic base in the US, which I will provide more details on in the next slide. Secondly, like-for-like sales grew by 15% for the period, impacted by an accelerated decline in Snus sales during the period. Third, the gross margin continues to increase to a record high of 18.8%, reflecting the strength of our operating model. And lastly, we have continued to make strides forward in our infrastructure overhaul, having successfully migrated our largest site onto our new infrastructure by year-end. We expect to have the two remaining smaller sites completed, bringing the overall project to an end. This new infrastructure is already enabling much more speed and agility and creates an excellent foundation for future growth. Moving to the next slide. Slide five focuses on the US performance. Our like-for-like sales volume in the US grew 40% year on year despite the high comparators from last year, which you can see here in the chart. In addition, we recognized the strong development in our new consumers in recent quarters, which is visible in the second chart. And lastly, in mid-September, we resumed sales of Zyn in the US. This comes on the back of a mutually beneficial agreement, where the brand will also utilize our media and insight services. We recognize that there are many Zyn loyal consumers who were forced to buy from other retailers over the past year, and we are now placing an emphasis on reactivating those consumers. Moving to slide six and the US outlook, the FDA is piloting a new approval process, which aims to process products from four of the leading manufacturers before the end of 2025. While this process doesn't guarantee that each product will be approved, it may signal an acceleration in the range of new products entering the US market. On the back of the ever-improving landscape in the US. Haypp Group is preparing to accelerate new consumer inflow. Haypp Group initiated a deep market analysis during Q3 with a third-party specialist firm. The goal of the analysis is to identify the evolving needs of different offline consumer segments and how to overcome impediments to their shopping online. This work is expected to be completed this year. In conjunction, Haypp Group has commissioned a marketing agency with specific expertise related to our business with the intent of engaging key consumer segments to accelerate our new consumer inflow. The learnings from our pilots this year, such as same day delivery, out-of-store advertising, referral and loyalty programs, are feeding into this marketing plan, and we expect it to be operational early in 2026. Moving to slide seven and our regulatory and legal update and starting with the US. In addition to the point in the prior slide regarding the FDA's pilot program to process a range of SKUs before year-end, we expect the most notable changes to occur around state-level excise taxes on Nicotine Pouches during 2026. As more information becomes available, we will continue to update you. It should also be noted that there is a referendum underway in Denver, Colorado, on a tobacco product flavor ban. Nicotine pouches are included in that categorization. Regarding the EU, in addition to the TCE, which we spoke of last quarter, the EU Commission is preparing a submission for the FCTC. These discussions are likely to generate a variety of headlines that, over time, will likely moderate, and we remain optimistic about the regulatory outlook for Europe, where the most regressive positions are opposed by member states led by Sweden. In the UK, the Tobacco and Vape Bill is currently being discussed in Parliament. We hope the bill will implement nicotine pouches product standards, which are in line with Haypp Group policies regarding litigation highlights. Legal proceedings in Stockholm are expected to take between 3 to 9 months. And regarding San Francisco, a settlement was reached during October. Removing US litigation uncertainty. With that, I will now hand over to Peter for an update on our financial performance. Thank you, Gavin. Good morning everyone. Before going to the details, I just.
I'd like to quickly summarize what you're going to see in our review. We concluded a solid quarter. As Gavin already elaborated on, we successfully relaunched Zyn, the market-leading brand on our US storefronts, and we maintained our gross margin, allowing us to initiate the necessary investment primarily towards the US market to lay the foundation for the next growth chapter. Despite the increased level of investments, our adjusted EBIT remained flat compared to the same period last year at 0.5%. On slide eight, let me begin with our sales development. Like-for-like comparison became even more complex because we have to adjust for the 2025 Q3 reported numbers as well to make the numbers comparable to 2020. For Q3, we had Zyn in the US for the full quarter, while in 2025 Q3 we sold this brand only for 19 days; reported sales grew by 1%. Excluding the effects of foreign exchange, the increase was 3%. Like-for-like sales growth was 15%. There is no change in the product composition of growth drivers. The 15% like-for-like growth is mainly driven by Nicotine Pouches, while Snus declined mainly in Sweden, impacting our performance negatively by 5%. This is partly offset by the contribution from the Emerging segment, which accounted for 2% of the growth. The Snus decline accelerated during the quarter. However, on a going forward basis, we expect it to moderate. On slide nine, we are going into more details about our like for like sales development. The key drivers include the net impact within the reported sales, driven by the US Zyn tobacco discontinuation and closing states, amounting to 92 million. As mentioned earlier, currency fluctuations have created a headwind for us. The impact of the foreign exchange movement remained in line with the first half of the year. The depreciation of the Norwegian krone and the US dollar against the Swedish krona has negatively affected reported sales. Zooming into the operational performance. All reporting segments contributed to the growth on a like-for-like basis. The growth segment in the US particularly remained the biggest driver, accounting for 54% of the operational growth. Core segment represented 29%, while the emerging segment accounted for 17%. Moving to slide ten and progressing a few lines down in the P&L, you can find the long-term quarterly development of Haypp Group's gross margin, both in absolute terms and as a percentage of net sales. Q3's margin level remained in line with the first half of 2025 compared to last year, not only in terms of the margin rate, but also the key drivers of increase. The sustained and robust margin performance is the foundation for the execution of our growth strategy in the U.S. This allows us to make the investments required to set the foundations for the next growth chapter. Important to note that going forward, the return of Zyn is not expected to negatively impact our margin levels. Sustaining a strong media and insights business will remain important, and the continued development of those products is pivotal for us. I would like to reaffirm the foundational principles of our business model. We allocate the value created by our company across our consumers, business partners, and shareholders. Our ongoing priority is to enhance the value we provide to consumers, which in turn requires us to strengthen the value we generate for our business partners by continuously improving our media and insights offerings. We are able to deliver greater value and convenience to our consumers, while also driving healthier profit margins over the medium term. On slide 11. You can see an overview of our overhead base, which increased by 226 million for the third quarter. This increase is mainly driven by the enhancement of the US local team capabilities. We also strengthened our media and insights teams and invested in activities to increase online channel and Haypp Group brand awareness. On slide 12, you can see key figures around our profitability. Adjusted EBIT for the third quarter grew by 0.9%, reaching 33.4 million. The adjusted Ebit margin remained flat at 3.5%. We benefited from the increased gross margin. However, this was offset by increased investments into overheads and marginally into paid marketing. The increase in depreciation, similar to previous quarters this year, is partly driven by the US Automation, which we installed mid-December last year. We maintained our investment in the emerging segment this quarter. The investment amounted to 13.1 million SEK and reduced the overall adjusted Ebit of the group by 1.6 percentage points. Adjusted EBIT for the core and growth business was 5.1%, growing 0.7 percentage points versus last year. Moving to slide 13 and zooming in on our core markets. This segment delivered an overall 5% constant currency net sales growth. The quarter started slow with some acceleration during the second half of the quarter behind the sales growth. Two completely different dynamics remained: the Nicotine Pouches segment, which accounted for 57% of the volume of our core markets, maintained its growth and consistently gained share within our volume. The Snus segment's volume remained in decline, and this decline accelerated in Q3 compared to the first half of the year. The decline was driven by the reduction in underlying consumer demand. It is also important to note that Q3 is the last quarter where the tax reduction-driven price decrease on the 1st of October, 2024, resulted in a negative price mix for the Swedish market in the Snus segment. These two opposite dynamics mean that the share increase of the fast-growing Nicotine Pouches segment will improve the overall growth rates of the core markets. The changes in the purchasing customer numbers also reflect the different dynamics. While we are continuously building on the Nicotine Pouches consumer base, the decline in Swedish Snus consumers has resulted in a strong adjusted EBITDA for this segment at 10% in Q3. This result is 1.3 percentage points above the same period last year. The driver behind the increase is the Media and insights revenue growth. On slide 14. You can find our gross market performance. Net sales excluding currency impact on a like-for-like basis are up by 39%. While all markets increased their sales. We are very pleased with the high double-digit growth rates of the US and the nicotine pouches volume development in the UK. Adjusted EBITDA moved into negative territory, driven by increased investment levels, mainly in the US. In absolute terms, it amounted to -1.4 million, and the adjusted EBITDA rate was -0.6%, while profitability is down compared to the same period last year. It's important to note that the gross margin remained stable for the segment. However, the overhead increase, mainly driven by the US, negatively impacted the business unit. On slide 15. What is the emerging segment? The sequential sales growth continued, and we are particularly pleased with the Swedish and German market performance. Unfortunately, operating in the UK market remained challenging due to the absence of regulatory enforcement across the entire spectrum of market participants. Haypp Group has always been and will always remain committed to complying with regulations. However, this can create a significant competitive disadvantage. In markets and segments where we are market leaders, we can compensate with our weight if other retailers are not complying. But in the UK market, as a challenger, the uneven playing field prevents us from achieving our ambitions. As you can see on the bottom chart, while net sales in Sweden and Germany maintain their growing trend, this was not the case in the UK. Despite the heavy investments we made both into our consumer offer and also into our internal capabilities. These factors led us to decide to discontinue or waive Heat-not-Burn sales in the UK during Q4. On page 16, I would like to highlight 3 or 4 selected KPIs. The full list of KPIs is available in the appendix of this presentation. Starting with the inventory, it increased compared to Q2, driven by the build-up of Zyn inventory in the US, with a slight reduction in inventories in other locations. The inventory increase didn't fully translate into an increase in our working capital, due to improvements in other components. Net debt to adjusted EBITDA ratio remained at 0.4 times. With this, I would like to hand back to Gavin.
Thank you very much, Peter. Moving on to our outlook slide. Slide 18. In our view, the long-term future for risk-reduced nicotine products, the online channel, and Haypp Group with its many strengths remains very encouraging. Conditions within the US continue to evolve in a positive direction for Haypp Group, and Haypp Group's operating model continues to generate increasing value for consumers and suppliers while also providing margin expansion opportunities over the medium term. The expected increase in regulatory requirements is beginning to manifest, which further differentiates us given our sustained focus and investment in long-term compliance. And finally, on slide 19, I would like to touch upon our medium-term guidance from the Capital Markets Day in April of this year, which runs out to 2028. We envision revenue growth rates of 18 to 25% over the period, with the US market being a significant contributor. This reflects the lower expected growth rates for 2025 due to the comparatively narrower consumer base in the US. We also guide towards 5.5% EBIT at the end of the period, plus or minus 150 basis points. While we have been materially increasing our EBIT over the past two years, we intend to reinvest into the US to accelerate our market share growth over this period. I would kindly direct your attention to our CMC material, which is available on our group site, and this provides more detail behind these targets. Lastly, the company does not intend to issue a dividend over this period, instead reinvesting surplus cash flows into the company's future expansion. Before I open up for questions, I would like to take the opportunity to thank my colleagues for their dedication and hard work in delivering these strong results. With that, I will hand over to the operator for questions.
If you wish to ask a question, please press the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Johan. Fred from SEB. Please go ahead.
Yeah. Good morning, everyone. Thank you for taking my questions. A couple of questions from my side. First one on Zyn. Now that Zyn is back in the US assortment, could you share any early indicators on the reactivation of dormant US customers? I saw that active customers declined by 25% year on year in Q3 in growth markets. But what did you observe from mid-September once Zyn returned in terms of traffic conversion, etc? ?
Good morning, Johan. Yes, absolutely. And if I take this question, perhaps in chronological order. So if I take a look back, first of all, at 2024, there was an exceptional number of customers, even relative to the volume, because we were rationing the volume of products and particularly of Zyn that any consumer could buy over a 30-day period during Q2 and particularly Q3 of 2024. Then moving along to this year. So yes, we know that there was a substantial number of consumers who came in, particularly during 2024, who then, of course, disappeared in the latter part of the quarter when we no longer had the product. And I guess there are two dynamics to those. Some of those were ones who were forced online because they couldn't get the product anywhere else. Some of these consumers chose to come online and quite enjoyed the experience. So there is a significant number of consumers there along the way. We have been working on reaching out to those consumers via different channels since the time Zyn returned, and we've been quite happy with the early successes we've made on that. However, we realize this is a substantial number of consumers, and we need to keep leaning into that to capture and reactivate as many of them as possible over the remainder of Q4.
Cool. Got it. And maybe if I can just dig a bit deeper into that topic, I wonder if you could walk us through your strategy here in rebuilding awareness in the US. Is this primarily CRM-driven, or will we see a step-up in paid acquisitions? And if so, what channels are you focusing on, and any sort of early insights from what you have at the end of September would be much appreciated.
Yes. It starts off with leveraging the lowest hanging fruit, which is primarily through CRM, regarding the ability to reach out to them initially via email. We're now looking at testing ways to follow up on that through other aspects as well, such as calling some of the consumers to let them know that we're back on this. And what we can see is that, just to be clear, in this instance, we're dealing with over 100,000 Zyn consumers who came to us in the first nine months of 2024, with a particular lean towards the periods between late March and late September. So this is a sizeable base of consumers within the US, and we see that we've gotten a good activation flow for perhaps the first 12 to 14,000 of those coming back in already. I think, like I said, there's still a sizable piece out there that we need to see how many of them we can reactivate. We're not naive enough to assume we can reactivate them all, but we are going to continue to expand the channels and the communication to them to get more and more of them in. These are extremely valuable consumers.
Got it. I saw that active customers declined by 25% year on year in Q3 in growth markets. Thank you so much for that additional color. And the final one here before I jump back in the queue is on the gross margin. Stepped up meaningfully in the quarter. But the adjusted EBIT margin did not expand to the same extent, which is reasonable given your investment in the US. But how should we think about operational gearing going into Q4 and 2026, now that it's fair to assume that volumes in the US will pick up significantly?
Yes. I think the way we were viewing this one is that we set out a very clear destination. One was a destination, but perhaps a milestone for where we would be in 2028. But we do expect that we will continue to invest in the US, as long as we can see strong returns on that investment that we're putting in. So we're not so much viewing this one from saying, this is exactly what our gross margin and EBIT and free cash flow will be for each quarter as we look out through 2026 and early 2027, but more a case of as long as we can see a strong return on capital, which we're investing, or we believe that there will be a strong return coming from the capital that we're investing, because some aspects are difficult to quantify exactly in advance. We will continue to invest that money. So I think there's probably more of that principle you should be considering this one through Johan with us, rather than a set target for what it will be for each quarter.
Got it? Got it. Makes perfect sense. Thank you. Those were all my questions. Now I will get back in the queue.
Thank you so much for that additional color. Thank you. Johan.
The next question comes from Nicolas Eekman from DMB Carnegie. Please go ahead.
Thank you. Yes. I have a couple of follow-up questions for you here. Is there any way you can quantify the current trading in the US market? And obviously, there are two effects here. Firstly, you come from a period of exceptionally tough comparisons and then there's the absence of Zyn. And now this completely reverses as we go into Q4. So I'm just trying to get a grasp on this. What kind of growth rates are you expecting? What kind of growth rates are you seeing now at the start of Q4 for both the US market and what kind of impact that has on the group? If there's any insight you could give us here, it would be appreciated.
Yes. No, exactly. I think you're spot on. So, I think there have been many factors contributing to it, as you mentioned. Firstly, looking backward, you were dealing with a scenario of not just the shortage of Zyn, but we had also discontinued tobacco, which has not completely run out when it comes to like-for-like, but it's a small enough part and it's been wound down quite heavily already by October of '24. And then there were the closed states. So then you have that. On one hand, all of the closed states were already being reflected and completed by the end of September 2024 as well. So then if you bring all of that together and you look at the initial growth coming through, I think what we can see here is that, for example, the October numbers are coming in with close to perhaps 60% volume growth in the US. Does that give you some form of guidance on where we are here?
Yep. Yep. Absolutely. Uh, and what kind of impact does that have on the group? What is the US roughly as a share of.
Sales currently constitute roughly 20% of the group's total sales and are growing substantially faster. So I guess you can reverse engineer back from that regarding what impact it could have on growth rates at the group level. Yes.
Very good. Second question on the same topic, and you reiterated here your guidance or your targets from the Capital Markets Day in April with growth rates of 18 to 25%. And that's a CAGR, adjusting for the weakness that we've seen in the last four quarters with growth rates of around 5%. So I guess my question here is, to me, that suggests you're expecting growth rates in the next four quarters to be well above the 18 to 25% range, more in the range of 30% plus, given the easy comparison base. Am I looking at this correctly?
Yes, we do expect the growth rates to pick up during 2026. Yes, exactly. Okay.
Good. Fair enough. And.
Yeah. And just to clarify, Nicholas, when I mention growth rates, I'm referring to reported growth rates as opposed to like-for-like, so the like-for-like rates will naturally be lighter. I'm going to be making the adjustment for having the extra assortment that I didn't have before.
So, will you continue to provide information on this? Yes. Will you continue to report like-for-like sales? I think that would be very helpful, particularly over the next four quarters when the comparisons are very easy.
We always endeavor to be helpful, Nicholas.
Very good, very good. Another question here is on the margin outlook. Again, coming back to the CMD guidance here regarding the margins of 4 to 7%. And the reason I'm asking is that I know there's some sell-side expectations that are significantly above that range, with margins, I think, coming close to 10%. But I know that the quality of the consensus might not be that great. So maybe I'm missing something here, but it seems like there are expectations for a very strong margin expansion in 2026 and 2027. And based on what we've seen on the gross margin, that seems to make sense. However, it doesn't align with your current guidance. So I'm again here, just trying to see if I'm missing something here, if there are any reasons why margins should be closer to 10% two or three years from now or. Yeah. Just to clarify your view there.
I think the guidance we gave for three years from now, which is 2028, is quite clear. We said we would be at around 5.5%, and given the growth opportunities manifesting at the time, it could be up to 150 basis points above or below. If we see growth opportunities starting to level out a little, well, then we will perhaps lean a little bit more towards the 150 basis points above. But everybody's entitled to their own opinions on where this will come in. But I don't know if we can be much clearer regarding what our expectation is.
Yeah. As of now, your growth markets have a much lower profitability than your core markets. And obviously you are now in a ramp-up phase where you have made a lot of recruitments, and your costs and volumes have only just started to come back. So structurally, is there any clear difference in profitability if you compare core markets to growth markets? And I'm thinking about the US market in particular, do you see that over time the US market could have the same level of profitability as you have in the Nordics?
I think the growth markets in general, and as you say, the US market in particular, are structured to achieve higher levels of profitability over the longer term. And I think the biggest factor for that is driven by the amount of opportunity provided to us by traditional offline retailers. Sweden is perhaps the most competitive market in the world when it comes to the retail environment for risk-reduced nicotine products, where you have extremely low retail margins. There are a lot of reasons for that. A lot of it goes back to when the industry had a completely different construct within Sweden, as far back as the 90s, and it has just been a legacy from there. But if you look at it, you're dealing with roughly 20% retail margins across the vast majority of the market in Sweden. First, you're dealing with 40 to 50% retail margins across markets like the US and the UK. So as I see it, the basis for long-term profitability is much greater in our growth markets than it is in our core markets. However, when it comes to us giving guidance for 2028, like I said earlier, I view 2028 very much as a milestone rather than a destination. So we believe that there will still be huge growth opportunities, even when we are dealing with the kind of market share that we laid out in the Capital Markets Day for both the US and the UK. So we're not necessarily stating that we will be at a steady state margin at that stage. We feel as though there will still be strong growth opportunities within those markets, and we believe there will be. We will continue to invest. But back, I think, to your initial question, or at least what I think your initial question was, Nicholas. And obviously, you are now in a ramp-up phase where you have made a lot of recruitments, and your costs and volumes have only just started to come back. I believe there is a basis for healthier margins in the growth markets than the core markets over the long term.
Very clear. And obviously you are now in a ramp-up phase where you have made a lot of recruitments and costs, and volumes have only just started to come back. And just a final question on this topic of the US or UK vaping and the Heat-not-Burn, how big a share was that of the. I think it was 40 million in revenue here in Q3. How significant a share was that? Did that make up part of the emerging segment?
Yeah, so it was just under a third of the emerging segment, between a quarter and a third. And so it accounts for just over one percentage point of our total group revenue. So, we consider it to be not particularly material in the scheme of things. And maybe just create a little more context on that one here. You know, there has been some very clear regulation introduced into the UK at various stages over the last couple of years, including earlier this year. It is an environment whereby many of the other retailers, both online and offline, are not complying with this and we're not prepared to go in and compete in that environment because it is illegal. That's not a space we operate within. I think it's also worth bearing in mind on this one, Nicholas, that the fastest growing category by far in the UK is Nicotine Pouches. And this gives us the opportunity to double down on our already very strong performance within the Nicotine Pouches, where we are the market leader and have a strong share of the online channel. So this gives us the opportunity to lean into that. And should the environment ever change when it comes to vape in the UK. And if we're sitting here in a few years' time and the regulation has been enforced and it's quite clear what the playing field is, we could very easily reverse the decision that we've made now. But at this point in time, we can't operate in an environment where we're one of the only ones complying with the regulation.
Do you see any risk that the discontinuation of vaping and Heat-not-Burn could negatively impact your momentum in Nicotine Pouches? Is there a big overlap in the number of users, and maybe the risk that you will lose some of these users because you don't have the full product portfolio?
No, I think vaping was quite useful to us a few years ago when Nicotine Pouches was in its infancy. You have to bear in mind, you know, nicotine pouches today are probably available in about four times as many stores in the UK as they are in Sweden. The availability of it is quite significant at this point in time. If you go back 2 to 3 years ago when nicotine pouches were in their infancy, it was a great opportunity for us to explain the category to the vaping consumers when they came in to buy vapes from us. We generally find that dual users of both categories tend to only remain dual users for about a quarter to a quarter and a half, at which point they usually switch entirely to Nicotine Pouches. There is an insignificant share of our sales made up of consumers who put both categories into a single basket. So we don't foresee any spillover effect from that.
That's very clear. Thank you so much for taking all my questions.
Thank you, Nicholas. But it is an environment where many of the other retailers, both online and offline, are not complying with this, and we're not prepared to go in and compete in that environment because it is illegal.
The next question comes from Morayo Adeshina from Barclays. Please go ahead.
Hello everyone. Thanks for taking my question. Just two quick questions from me on the FDA pilot. I was just wondering if Haypp has any insight into the timings of that and if things are going according to plan? And if the reviews are still expected to be completed on the Nicotine Pouches for this year, or is that something only privy to the manufacturers? And then secondly, on the Snus consumer demand decline in Sweden. Are you seeing a direct switch from Snus users to Nicotine Pouches? Is there any way of tracking this, or is that not really the right way to think about the decline? Yeah, those are my two questions.
Perfect. Let me start with the first one. Yeah. I think the position that the FDA has taken is quite clear and public with their commitment to having the pilot process completed by the end of 2025. I'm not sure, actually, that anybody has sufficient clarity on what's going on within the FDA regarding where they are in the process, because I am aware that we're now on the 5th of November, which means, best case scenario, I think they have probably about 6 to 7 weeks to get this completed. You can clearly get a sense from all stakeholders involved of how quickly people are preparing for a new environment here. I think what we're going to have to do is wait and see whether the FDA is going to be able to actually comply with the timeline they've laid out for themselves here. And I don't think I'm a bit dubious of anybody who is able to say that they have a clear view on this with certainty. I think there are a lot of unknowns in this, and we will know a lot more over the next couple of months. Unfortunately, I don't have a direct inroad to provide an answer on that one. And back to your second one regarding the Snus decline. Yeah. So I think there are a couple of factors here which are occurring within the mix of oral nicotine usage in Scandinavia, involving both the combination of Snus and Nicotine Pouches. One factor is that there are effectively no new entrants. I reckon there is somewhere around about 70 to 80,000 new entrants coming into the oral category in any given year in Sweden at this point in time. And I would say very few of those are entering the traditional Snus category, and this has been the case over the last 3 to 4 years. They're generally leapfrogging that and going straight to the Nicotine Pouches at the other end of the journey. And a lot of the older Snus users, a lot of the older users of oral products within Scandinavia are traditional Snus users. So when they're quitting, their Snus usage is often due to end of life or any other aspect like that. It tends to be disproportionately leaning towards those consumers rather than Nicotine Pouches consumers. And then in between is the third factor, which you were referring to, which is the switching pattern. And the switching pattern was perhaps a little bit more pronounced between 2019 and the early part of 2024. There is still a degree of it, but every consumer who wants to switch from Snus to Nicotine Pouches has been given a serious opportunity to do so over the last 5 or 6 years, so there aren't very many left who are actually willing to make the change. So I would say it's probably more the first two factors driving the lack of new entrants into traditional Snus, hence the natural decline of users within traditional Snus.
Is there any way of tracking this, or is that not really the right way to think about the decline? Thank you.
Perfect. Thank you very much.
The next question comes from Johan Fred from CIB. Please go ahead.
Yes. Hi again. A quick follow-up from my side on Zyn in the US too. To what extent is Zyn demand providing incremental versus substitution from non-Zyn pouches in the US? My question is really, have you seen any cannibalization of sales on other brands since you've returned in September? The next question comes from Johan Fred from CIB.
In short, the answer is yes, we have. So we've seen Zyn resonate quite well across our consumer base, with many consumers staying with us but changing brands. So there was a change in behavior. And then when Zyn came back, it became part of the repertoire again. So you can certainly see a strong degree of that. Yes.
Very clear. The next question comes from Johan Fred from CIB.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you very much for your time today. It's greatly appreciated and I look forward to speaking to you during our Q4 release in early February. The next question comes from Johan Fred from CIB. Bye bye.
Thank you, everyone. Bye.



















